TRT and men's health marketing agency for telehealth brands

It depends on scope: which platforms you run, how much new creative you need, and how many landing pages your lab and visit offers need. MedScale sets the fee after a free Growth Audit of your ads, site and tracking, so you see the plan and the fee before you commit. MedScale works month to month. Ad spend is separate: you pay Meta and Google directly from your own ad accounts, which stay in your name.

Yes, in two layers. Ads for the clinic, the labs and the visit run without authorization, because Meta exempts ads that only promote telehealth services generally. Naming testosterone needs active LegitScript certification, Meta's authorization, 18+ targeting in the US, Canada or New Zealand, and a disclaimer to consult a licensed health professional. Meta's personal-attributes rule still applies: "testosterone therapy is available" passes, "low T?" does not. MedScale runs TRT on Meta lab-first, with no bodies in the ads.

Yes, once a telehealth brand is certified. A telemedicine provider needs LegitScript plus Google's prescription drug services certification before its prescription drug ads serve in the US. Google lets US advertisers name testosterone in ad text and on landing pages without certification, but bidding on keywords that contain it needs certification. Enclomiphene and peptides fall under Google's unapproved pharmaceuticals rule and can't be advertised. MedScale builds TRT search campaigns on clinic and lab intent first, then adds drug-term keywords once certified.

Not testosterone itself, as of October 2026. TikTok's drugs policy lists controlled drugs among the things ads and landing pages can't promote, and testosterone is Schedule III. Its US prescription exception needs regulator approval and an 18+ audience, and compounded testosterone is compounded, not FDA-approved. A men's health clinic may run 18+ awareness ads about its clinicians, labs and visits, with no drug named and no performance angle, once TikTok confirms the plan in writing. The testosterone offer runs on Meta and Google.

For now, the model holds. DEA's fourth temporary extension lets registered practitioners prescribe Schedule II to V controlled substances, testosterone included, by telemedicine without an in-person evaluation through December 31, 2026. What comes after depends on what DEA publishes next. So MedScale's ads sell the program, the labs and the clinician, never a prescription with no visit, and MedScale keeps a landing page and intake variant ready for an in-person or hybrid first visit. Your healthcare counsel confirms the prescribing model.

Yes, within each platform's limits. Meta allows ED ads to people 18 and over when they focus on medical efficacy rather than pleasure, and naming sildenafil, tadalafil or finasteride needs LegitScript and Meta's authorization. On Google, an online ED or hair loss service that prescribes is a telemedicine provider and needs certification before its ads serve. TikTok's adult content policy bars ads for sexual-performance drugs, so ED medication stays off TikTok, and cosmetic products can't claim to treat hair loss there.

No. Patient numbers depend on platform review, auction prices, your offer and how your labs and visits convert, and no one controls all of those. What MedScale does promise: 8 ads at launch, every ad and page checked against platform rules before submission, server-side tracking under a BAA through labs, visit and prescription, and a written report every Monday on what each dollar produced. MedScale works month to month, so you stay because the numbers work.

Not as a product. Enclomiphene is not an FDA-approved drug, so it sits under the unapproved-pharmaceuticals rule on Google and the unapproved-substances reading on Meta. The ad names the program and the provider; enclomiphene is explained on the page after the click.

No, but it adds a review layer. LegitScript examines prescribing and dispensing practices for controlled substances, and the platforms flag controlled-substance promotion separately from ordinary prescription drugs. The creative stays on the program and the labs so that flag never has a reason to fire.

Usually peptides or a compounded product on the landing page or in an ad. The rescue is to remove the unapproved products from every page the ad can reach, rebuild the creative around the clinic, and appeal with evidence. An appeal only has a chance once the site changes.

The click ID is carried into the intake platform in a bridge token, and the consult and prescription events are sent back server-side with that token attached. The campaign gets the patient, not the form fill.